tbuckley/cabot-search huggingface dataset:
Trends in Opioid and Psychotropic Prescription in Pregnancy in the United States From 2001 to 2015 in a Privately Insured Population
Authors: Kartik K. Venkatesh, Virginia Pate, Kim A. Boggess, Hendrée E. Jones, Michele Jonsson Funk, Marcela C. Smid
Journal: Annals of Internal Medicine (2020)

Background: Opioid and psychotropic prescriptions are common during pregnancy. Little is known about coprescriptions of both medications in this setting. Objective: To describe opioid prescription among women who are prescribed psychotropics compared with women who are not. Design: Cross-sectional study. Setting: U.S. commercial insurance beneficiaries from MarketScan (2001 to 2015). Participants: Pregnant women at 22 weeks' gestation or greater who were insured continuously for 3 months or more before pregnancy through delivery. Measurements: Opioid prescription, dosage thresholds (morphine milligram equivalents [MME] of ≥50/day and ≥90/day), number of opioid agents (≥2), and duration (≥30 days) among those with and without prescription of psychotropics, from 2011 to 2015. Results: Among 958 980 pregnant women, 10% received opioids only, 6% psychotropics only, and 2% opioids with coprescription of psychotropics. Opioid prescription was higher among women prescribed psychotropics versus those who were not (26.5% vs. 10.7%). From 2001 to 2015, psychotropic prescription overall increased from 4.4% to 7.6%, opioid prescription without coprescription of psychotropics decreased from 11.9% to 8.4%, and opioids with coprescription decreased from 28.1% to 22.0%. Morphine milligram equivalents of 50 or greater per day decreased for women with and without coprescription (29.6% to 17.3% and 22.8% to 18.5%, respectively); MME of 90 or greater per day also decreased in both groups (15.0% to 4.7% and 11.5% to 4.2%, respectively). Women prescribed opioids only were more likely to have an antepartum hospitalization compared with those with neither prescription, as were women with coprescription versus those prescribed psychotropics only. Compared with those prescribed opioids only, women with coprescriptions were more likely to exceed MME of 90 or greater per day and to be prescribed 2 or more opioid agents and for 30 days or longer. Number and duration of opioids increased with benzodiazepine and gabapentin coprescription. Limitation: Inability to determine appropriateness of prescribing or overdose events. Conclusion: Opioids are frequently coprescribed with psychotropic medication during pregnancy and are associated with antepartum hospitalization. A substantial proportion of pregnant women are prescribed opioids at doses that increase overdose risk and exceed daily recommendations. Primary Funding Source: None.
Flavanol-Rich Cocoa: A Promising New Dietary Intervention to Reduce Cardiovascular Risk in Type 2 Diabetes?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Umberto Campia, Julio A. Panza
Journal: Journal of the American College of Cardiology (2008)
Advances in the Assessment of No-Reflow After Successful Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction: Now That We Can Diagnose It, What Do We Do About It?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Paul A. Grayburn, James W. Choi
Journal: Journal of the American College of Cardiology (2008)
179P Regorafenib combined with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) with previous systematic treatment: A preliminary investigation of safety and efficacy
Authors: Y. Han, G. Cao, B. Sun, J. Wang, D. Yan, H. Xu, Q. Shi, Z. Liu, L. Xu, B. Liu, Y. Zou
Journal: Annals of Oncology (2020)
Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international <scp>Sickle Cell World Assessment Survey</scp> (<scp>SWAY</scp>)
Authors: Ifeyinwa Osunkwo, Biree Andemariam, Caterina P. Minniti, Baba P. D. Inusa, Fuad El Rassi, Beverley Francis‐Gibson, Alecia Nero, Cassandra Trimnell, Miguel R. Abboud, Jean‐Benoît Arlet, Raffaella Colombatti, Mariane de Montalembert, Suman Jain, Wasil Jastaniah, Erfan Nur, Marimilia Pita, Laurie DeBonnett, Nicholas Ramscar, Tom Bailey, Olivera Rajkovic‐Hooley, John James
Journal: American Journal of Hematology (2020)

Abstract Sickle cell disease (SCD) is a genetic disorder, characterized by hemolytic anemia and vaso‐occlusive crises (VOCs). Data on the global SCD impact on quality of life (QoL) from the patient viewpoint are limited. The international Sickle Cell World Assessment Survey (SWAY) aimed to provide insights into patient‐reported impact of SCD on QoL. This cross‐sectional survey of SCD patients enrolled by healthcare professionals and advocacy groups assessed disease impact on daily life, education and work, symptoms, treatment goals, and disease management. Opinions were captured using a Likert scale of 1‐7 for some questions; 5‐7 indicated “high severity/impact.” Two thousand one hundred and forty five patients (mean age 24.7 years [standard deviation (SD) = 13.1], 39% ≤18 years, 52% female) were surveyed from 16 countries (six geographical regions). A substantial proportion of patients reported that SCD caused a high negative impact on emotions (60%) and school achievement (51%) and a reduction in work hours (53%). A mean of 5.3 VOCs (SD = 6.8) was reported over the 12 months prior to survey (median 3.0 [interquartile range 2.0‐6.0]); 24% were managed at home and 76% required healthcare services. Other than VOCs, fatigue was the most commonly reported symptom in the month before survey (65%), graded “high severity” by 67% of patients. Depression and anxiety were reported by 39% and 38% of patients, respectively. The most common patient treatment goal was improving QoL (55%). Findings from SWAY reaffirm that SCD confers a significant burden on patients, epitomized by the high impact on patientsʼ QoL and emotional wellbeing, and the high prevalence of self‐reported VOCs and other symptoms.
Abstract 14403: Mortality After Micra Leadless Pacemaker Implantation
Authors: Akshay R Kamath, Brittney Z Heard, Andrew E Darby, Rohit Malhotra, James M Mangrum, Kenneth C Bilchick, Pamela K Mason, John D Ferguson, Nishaki K Mehta
Journal: Circulation (2018)

Introduction: The Micra Transcatheter Pacing Study and early Post-Approval Registry data support the safety of the Medtronic Micra transcatheter pacing system (MTPS), but non-industry sponsored mor...
15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial
Authors: Gil Yosipovitch, Thomas Bieber, Linda Stein Gold, Shawn Kwatra, Svitlana Tatulych, Chudy Nduaka, Michael C. Cameron, David Williams, Pinaki Biswas, Hernan Valdez
Journal: Journal of the American Academy of Dermatology (2020)
Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity
Authors: Gonzalo R. Sequeira, Ana Sahores, Tomás Dalotto-Moreno, Ramiro M. Perrotta, Gabriela Pataccini, Silvia I. Vanzulli, María L. Polo, Derek C. Radisky, Carol A. Sartorius, Virginia Novaro, Caroline A. Lamb, Gabriel A. Rabinovich, Mariana Salatino, Claudia Lanari
Journal: Cancer Research (2020)

The role of active antitumor immunity in hormone receptor-positive (HR
Psychedelics in Psychiatry—Keeping the Renaissance From Going Off the Rails
Authors: David B. Yaden, Mary E. Yaden, Roland R. Griffiths
Journal: JAMA Psychiatry (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Cholesteryl Ester Transfer Protein Inhibition: The Next Frontier in Combating Coronary Artery Disease?⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Richard V. Milani, Carl J. Lavie
Journal: Journal of the American College of Cardiology (2006)
ADAR1 Stimulation by IFN-α Downregulates the Expression of MAVS via RNA Editing to Regulate the Anti-HBV Response
Authors: Tao Li, Xiaoshuang Yang, Wei Li, Jiaru Song, Zhuo Li, Xilin Zhu, Xiaopan Wu, Ying Liu
Journal: Molecular Therapy (2020)

The partial response of chronic hepatitis B virus (CHB) patients to interferon-α (IFN-α) therapy remains elusive, which requires a better understanding of the involved molecular mechanism. In our study, bioinformatics analysis was applied to relate IFN-α regulated candidate genes and RNA editing sites by RNA sequencing. Mitochondrial antiviral signaling protein (MAVS) antiviral effect was confirmed in HepG2.2.15 cells and in two mouse models. The associations between polymorphisms in MAVS gene and response to IFN-α therapy were confirmed in CHB patients. We found that IFN-α downregulates MAVS via RNA editing that was mediated by adenosine deaminase acting on RNA (ADAR1). ADAR1 inhibited MAVS expression via a human antigen R (HuR)-mediated post-transcriptional regulation. MAVS exerted an antiviral activity and reduced the level of hepatitis B virus (HBV) markers in vitro and in vivo. IFN-α antiviral effects were significantly enhanced by MAVS co-transfection. Hepatitis B core protein (HBc) interacted with SP1 to inhibit the promoter activity of MAVS that regulates its expression. CHB patients with a rs3746662A allele had higher MAVS expression and thus were more responsive to IFN-α treatment. In this work, we demonstrated that the decrease of MAVS expression is mediated by the IFN-α-ADAR1 axis. This study also highlighted the potential for the clinical application of MAVS in combination with IFN-α for the treatment of HBV infection.
13350 Psoriasis outcomes in a randomized trial of etanercept and methotrexate as monotherapy or in combination in patients with psoriatic arthritis
Authors: Joseph F. Merola, Alice B. Gottlieb, Philip Mease, Vibeke Strand, Arthur Kavanaugh, Lyrica Liu, James B. Chung, Gregory Kricorian
Journal: Journal of the American Academy of Dermatology (2020)
Longitudinal Analyses Suggest Genomic and Psychological Origins of Disordered Eating and Comorbidities
Authors: Moritz Herle, Carol Kan
Journal: JAMA Network Open (2020)

Lauren Robinson, PhD; Zuo Zhang, PhD; Tianye Jia, PhD; Marina Bobou, MSc; Anna Roach, MSc; Iain Campbell, PhD; Madeleine Irish, MSc; Erin Burke Quinlan, PhD; Nicole Tay, PhD; Edward D. Barker, PhD; Tobias Banaschewski, MD, PhD; Arun L. W. Bokde, PhD; Antoine Grigis, PhD; Hugh Garavan, PhD; Andreas Heinz, MD, PhD; Bernd Ittermann, PhD; Jean-Luc Martinot, MD, PhD; Argyris Stringaris, MD, PhD; Jani Penttilä, MD, PhD; Betteke van Noort, PhD; Yvonne Grimmer, MD; Marie-Laure Paillère Martinot, MD, PhD; Corinna Insensee, PhD; Andreas Becker, PhD; Frauke Nees, PhD; Dimitri Papadopoulos Orfanos, PhD; Tomáš Paus, MD, PhD; Luise Poustka, MD; Sarah Hohmann, MD; Juliane H. Fröhner, MSc; Michael N. Smolka, MD; Henrik Walter, MD, PhD; Robert Whelan, PhD; Gunter Schumann, MD; Ulrike Schmidt, MD, PhD; Sylvane Desrivières, PhD; IMAGEN Consortium
US State Government Crisis Standards of Care Guidelines
Authors: Andrew Hantel, Jonathan M. Marron, Michael Casey, Sharyn Kurtz, Emily Magnavita, Gregory A. Abel
Journal: JAMA Oncology (2020)

<h3>Importance</h3> State crisis standards of care (CSC) guidelines in the US allocate scarce health care resources among patients. Anecdotal reports suggest that guidelines may disproportionately allocate resources away from patients with cancer, but no comprehensive evaluation has been performed. <h3>Objective</h3> To examine the implications of US state CSC guidelines for patients with cancer, including allocation methods, cancer-related categorical exclusions and deprioritizations, and provisions for blood products and palliative care. <h3>Design, Setting, and Participants</h3> This cross-sectional population-based analysis examined state-endorsed CSC guidelines published before May 20, 2020, that included health care resource allocation recommendations. <h3>Main Outcomes and Measures</h3> Guideline publication before or within 120 days after the first documented US case of coronavirus disease 2019 (COVID-19), inclusion of cancer-related categorical exclusions and/or deprioritizations, provisions for blood products and/or palliative care, and associations between these outcomes and state-based cancer demographics. <h3>Results</h3> Thirty-one states had health care resource allocation guidelines that met inclusion criteria, of which 17 had been published or updated since the first US case of COVID-19. States whose available hospital bed capacity was predicted to exceed 100% at 6 months (χ<sup>2</sup> = 3.82;<i>P</i> = .05) or that had a National Cancer Institute–designated Comprehensive Cancer Center (CCC; χ<sup>2</sup> = 6.21;<i>P</i> = .01) were more likely to have publicly available guidelines. The most frequent primary methods of prioritization were the Sequential Organ Failure Assessment score (27 states [87%]) and deprioritizing persons with worse long-term prognoses (22 states [71%]). Seventeen states' (55%) allocation methods included cancer-related deprioritizations, and 8 states (26%) included cancer-related categorical exclusions. The presence of an in-state CCC was associated with lower likelihood of cancer-related categorical exclusions (multivariable odds ratio, 0.06 [95% CI, 0.004-0.87]). Guidelines with disability rights statements were associated with specific provisions to allocate blood products (multivariable odds ratio, 7.44 [95% CI, 1.28-43.24). Both the presence of an in-state CCC and having an oncologist and/or palliative care specialist on the state CSC task force were associated with the inclusion of palliative care provisions. <h3>Conclusions and Relevance</h3> Among states with CSC guidelines, most deprioritized some patients with cancer during resource allocation, and one-fourth categorically excluded them. The presence of an in-state CCC was associated with guideline availability, palliative care provisions, and lower odds of cancer-related exclusions. These data suggest that equitable state-level CSC considerations for patients with cancer benefit from the input of oncology stakeholders.
AB0021 IMMUNOGENICITY OF TNF ALPHA ANTAGONISTS IN RHEUMATIC INFLAMMATORY DISEASES : IMPACT ON CLINICAL RESPONSE
Authors: Selma Bouden, Lilia Laadhar, Imen Ayadi, Mariam Sallemi
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> One of the mechanisms implicated in the loss of response to TNF alpha antagonists in rheumatic inflammatory diseases is the formation of antibodies against these drugs (anti-drug antibodies: ADAb). <h3>Objectives:</h3> The objective of our study was to determine the incidence of ADAb anti Infliximab (IFX) and anti Adalimumab (ADA) and to evaluate the therapeutic impact of the presence of ADAb, the rate of ADAb and trough serum concentration of the drug at the time of sampling and six months later. <h3>Methods:</h3> A longitudinal, prospective and multicenter study was conducted including patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) treated with IFX or ADA as a first biotherapy for at least six months. ADAb and trough levels were measured. The evaluation of the therapeutic response was made at the time of sampling and six months later. <h3>Results:</h3> Fifty patients were included (17 RA and 33 SpA). ADAb were positive in 39% of SpA and 35% of RA. They were positive in 40% of cases for IFX and 25% for ADA. The presence of ADAb was negatively related to the trough levels of IFX and ADA during RA (p=0.01 and p&lt;0.0001) and SpA (p&lt;0.01 and p&lt;0.0001). For the two pathologies, no impact of the presence of ADAb, the rate of ADAb or the trough levels was noted on the therapeutic response at the time of sampling. However, the presence of ADAb was related to a higher activity of SpA six months after the sampling (p=0.05). Factors that were related to ADAb formation were a high BMI in RA (p=0.05) and a longer duration of evolution of RA (p=0.03). <h3>Conclusion:</h3> The presence of ADAb and low trough levels seem to not affect the therapeutic response in patients on TNF alpha antagonists. Other tracks than immunogenicity should be investigated to explain the loss of response to these biotherapies. <h3>Disclosure of Interests:</h3> None declared
Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology
Authors: Matthew P. Giannetti, Cem Akin, Raied Hufdhi, Matthew J. Hamilton, Emily Weller, Bjorn van Anrooij, Jonathan J. Lyons, Jason L. Hornick, Geraldine Pinkus, Mariana Castells, Olga Pozdnyakova
Journal: Journal of Allergy and Clinical Immunology (2020)
Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19
Authors: Gregory Piazza, David A. Morrow
Journal: JAMA (2020)

Seda Bilaloglu, MS; Yin Aphinyanaphongs, MD, PhD; Simon Jones, PhD, MSc; Eduardo Iturrate, MD, MSW; Judith Hochman, MD; Jeffrey S. Berger, MD, MS
Barong: reaching out to where things happen in Brazil
Authors: Joe Parkin Daniels
Journal: The Lancet HIV (2020)

With Brazil's HIV/AIDS response beset by the ongoing COVID-19 pandemic and the antiscience approach from president Jair Bolsonaro, civil society organisations are picking up the slack, even as funds from international donors dwindle. The Barong Cultural Institute, formed in 1996 in São Paulo and working across 50 municipalities nationwide, has long sought to bring a holistic and non-judgmental approach to HIV/AIDS outreach in Brazil, as part of a wider strategy to promote sexual and reproductive health education.
Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study
Authors: Jan Beyer-Westendorf, Luise Tittl, Ingrid Bistervels, Saskia Middeldorp, Christof Schaefer, Wolfgang Paulus, Will Thomas, Bettina Kemkes-Matthes, Sandra Marten, Martin Bornhauser
Journal: The Lancet Haematology (2020)
18F-FDG PET and 18F-FDG PET/CT in Vulvar Cancer
Authors: Elizabeth K.A. Triumbari, Elizabeth J. de Koster, Vittoria Rufini, Simona M. Fragomeni, Giorgia Garganese, Angela Collarino
Journal: Clinical Nuclear Medicine (2020)

Aim The aims of this study were to determine the role of 18 F-FDG PET/CT in vulvar cancer patients and to extract summary estimates of its diagnostic performance for preoperative lymph node staging. Patients and Methods PubMed/Medline and Embase databases were searched to identify studies evaluating 18 F-FDG PET/CT in vulvar cancer patients. The assessment of methodological quality of the included articles was performed. Per-patient and per-groin pooled estimates, with 95% confidence intervals (CIs), of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic odds ratio (DOR) were calculated. Results Ten articles were included in the systematic review, 7 among which evaluated the diagnostic performance of preoperative 18 F-FDG PET/CT for lymph node staging. Qualitative per-patient analysis (72 patients from 4 studies) resulted in estimated pooled sensitivity, specificity, PPV, NPV, and DOR of 0.70 (95% CI, 0.44–0.95), 0.90 (95% CI, 0.76–1.04), 0.86 (95% CI, 0.66–1.06), 0.77 (95% CI, 0.56–0.97), and 10.49 (95% CI, 1.68–65.50), respectively. Qualitative per-groin analysis (245 groins from 5 studies) resulted in estimated pooled sensitivity, specificity, PPV, NPV, and DOR of 0.76 (95% CI, 0.57–0.94), 0.88 (95% CI, 0.82–0.94), 0.70 (95% CI, 0.55–0.85), 0.92 (95% CI, 0.86–0.97), and 19.43 (95% CI, 6.40–58.95), respectively. Conclusions Despite limited literature data, this systematic review and meta-analysis revealed that a negative preoperative PET/CT scan may exclude groin metastases in at least early-stage vulvar cancer patients currently unfit for sentinel node biopsy and select those eligible for a less invasive surgical treatment. A positive PET/CT result should otherwise be interpreted with caution. Larger prospective studies are needed to confirm these results and to evaluate the diagnostic value of standardized semiquantitative analysis compared with the qualitative one.
14216 Long-term treatment effects of ixekizumab among psoriasis patients who achieved early high-level treatment outcomes in a real-world setting: Results from a single US dermatology referral practice
Authors: Craig Leonardi, Rei Tao, Solmaz Setayeshgar, Sisi Wang, Suzanne McMullen, Russel Burge, Baojin Zhu, WIlliam Malatestinic
Journal: Journal of the American Academy of Dermatology (2020)
Abstract 17300: The Effect of Fatty Acid on the Maturation of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Authors: Yuichi Horikoshi, Xiaowen Bai, Yasheng Yan, Maia Terashvili, Wai-Meng Kwok, Satoshi Fujita, Zeljko Bosnjak
Journal: Circulation (2017)

Introduction: Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CMs) is a potentially promising therapeutic strategy for patients with heart disease. However, iPSC-CMs exhibit imma...
15274 Dupilumab improves patient-reported global assessments of disease severity and treatment effect: Data from a 16-week phase 3 placebo-controlled trial in adolescent patients with moderate to severe AD (LIBERTY AD ADOL)
Authors: Eric L. Simpson, Emma Guttman, Ashish Bansal, Zhen Chen, Ana Beatris Rossi, Abhijit Gadkari
Journal: Journal of the American Academy of Dermatology (2020)